Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

SER-301 & Ulcerative Colitis (UC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

SER-301 from Seres Therapeutics Inc. is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate Ulcerative Colitis (UC). It has been studied in early-phase clinical trials for patients with mild-to-moderate UC (1, 2). No results or definitive efficacy data are available from published late-stage trials as of November 2025 .

References:

(1) Nelson et al. 2021 Gastroenterology 160(6 Suppl.): S324-S325
(2) Martinez et al. 2021 Gastroenterology 160(6): S-135

…

References (Sources)

In vivo characterization of SER-301, an investigational rationally-designed microbiome therapeutic for patients with active mild-to-moderate ulcerative colitis
Nelson et al. 2021 Gastroenterology 160(6 Suppl.): S324-S325
SER-301, an investigational, rationally-designed bacterial consortium for mild-to-moderate ulcerative colitis, recapitulates the effects of SER-287, a consortium of firmicute spores, on remission associated microbial metabolites and host gene expression
Martinez et al. 2021 Gastroenterology 160(6): S-135

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!